At a glance
- Originator Burroughs Wellcome
- Class Antidepressants; Anxiolytics
- Mechanism of Action Monoamine oxidase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 17 Jan 2001 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 17 Jan 2001 No-Development-Reported for Depression in USA (Unknown route)
- 09 Feb 1999 Preclinical development for Anxiety disorders in USA (Unknown route)